Skip to content

Press Releases

Filter Releases
 
Press Releases
Date Title and Summary View
Aug 31, 2017
ATLANTA, Aug. 31, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three months and fiscal year ended June 30, 2017. "We have made great strides, working with our Board and financial advisors, in honing in on a select number of strategic alternatives," commented Joseph M. Patti,...
May 4, 2017
ATLANTA, May 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended March 31, 2017, which is the third quarter of the Company's 2017 fiscal year. "We are expeditiously working with our Board and financial advisors to consider a wide range of strategic altern...
Apr 4, 2017
ATLANTA, April 04, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced that based on a review of the status of its internal programs, resources and capabil...
Feb 13, 2017
ATLANTA, Feb. 13, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics (NASDAQ:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its Phase 2b SPIRITUS trial, a multi-center, randomized, double-blind, p...
Feb 2, 2017
ATLANTA, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended December 31, 2016, which is the second quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. "In looking to the 2017 calendar year, we hav...
Feb 1, 2017
ATLANTA, Feb. 01, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (Nasdaq:AVIR), a company focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options, today announced top-line data from its double-blind, placebo-controlled Phase 2a study of BTA585 in a...
Jan 26, 2017
ATLANTA, Jan. 26, 2017 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, February 2, 2017 at 4:30 p.m. ET to review the Company's financial results for the three month period ended De...
Nov 9, 2016
ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen's CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 201...
Nov 3, 2016
ATLANTA, Nov. 03, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the three month period ended September 30, 2016, which is the first quarter of the Company's 2017 fiscal year, and also provided an update on recent corporate developments. "Throughout the last quarter and in recent ...
Oct 27, 2016
ATLANTA, Oct. 27, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, November 3, 2016 at 4:30 p.m. ET to review the Company's financial results for the three month period ended Se...
Oct 10, 2016
ATLANTA, Oct. 10, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing burden of human rhinovirus (HRV) infections in at-risk patient populations on Thursday, O...
Sep 14, 2016
ATLANTA, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) today announced its financial results for the fourth quarter and 2016 fiscal year ended June 30, 2016, and also provided an update on recent corporate and clinical developments. "Over the last twelve months we have made significant advances with our three n...
Sep 13, 2016
ATLANTA, Sept. 13, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Wednesday, September 14, 2016 at 4:30 p.m. ET to review the Company's financial ...
Sep 7, 2016
ATLANTA, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that Aviragen's CEO & President Joseph Patti, PhD will present a corporate overview at the following upcoming conferences: ...
Sep 6, 2016
ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the Company has granted two new hires options to purchase an aggregate of 125,000 shares of the Company's common stock wit...
Sep 6, 2016
ATLANTA, Sept. 06, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that it is delaying the time of its fourth quarter and fiscal year end 2016 earnings conference call and webcast while it conc...
Sep 1, 2016
ATLANTA, Sept. 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, September 8, 2016 at 4:30 p.m. ET to review the Company's financial re...
Jul 12, 2016
ATLANTA, July 12, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced it is resuming enrollment in its Phase 2a challenge study of BTA585, an oral fusion inhibitor in development for the treatment a...
Jul 5, 2016
ATLANTA, July 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has entered into an exclusive, worldwide license and sponsored research agreement with Georgia State University Research...
Jul 1, 2016
ATLANTA, July 01, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, announced today that the compensation committee of the Company's Board of Directors granted to Jonas Niaura, Vice President of Business Developm...
Jun 28, 2016
ATLANTA, June 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced the appointment of Jonas Niaura as Vice President, Corporate Development and Strategy. "Jonas brings to Aviragen considerable business development experience in t...
May 26, 2016
ATLANTA, May 26, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.), a pharmaceutical company that is developing the next generation of antivirals, today announced that it has voluntarily decided to delay further enrollment in the Phase 2a trial of BTA585 for the treatment of RSV infections b...
May 5, 2016
ATLANTA, May 05, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) today announced its financial results for the three month period ended March 31, 2016, which is the third quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate and clinical developments. ...
Apr 28, 2016
ATLANTA, April 28, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that management will host a conference call on Thursday, May 5, 2016 at 4:30 p.m. ET to review the Company's financial results f...
Apr 25, 2016
ATLANTA, April 25, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR) (formerly Biota Pharmaceuticals, Inc.) a pharmaceutical company that is developing the next generation of antivirals, today announced that it has signed a definitive agreement to receive a cash payment of $20 million from HealthCare Royalty Partners in exchange ...
Apr 14, 2016
ATLANTA, April 14, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc., (NASDAQ:AVIR), formerly Biota Pharmaceuticals, Inc., today announced that Joseph Patti, PhD, President & CEO of Aviragen Therapeutics, will participate in a panel discussion titled, "Notable Emerging Anti-Viral Agents" as part of the FBR & Co. New Prescriptions: Innovation i...
Apr 12, 2016
ATLANTA, April 12, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that the Company has changed its name to Aviragen Therapeutics, Inc., ("Aviragen Therapeutics"), a pharmaceutical company focused on the development of the next generation of direct-acting antivirals that address infections that have limited ther...
Apr 11, 2016
ATLANTA, April 11, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, today announced the initiation of its Phase 2a challenge study of BTA585, an oral fusion inhibitor in...
Apr 6, 2016
ATLANTA, April 06, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate overview and ...
Mar 17, 2016
ATLANTA, March 17, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced that it has completed the sale of assets related to its broad spectrum antibiotic program to a newly formed subsidiary of Spero Therapeutics, LLC, a Cambridge-based biopharmaceutical company founded to develop novel therapies for the treatment of...
Mar 7, 2016
ATLANTA, March 07, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corpora...
Feb 26, 2016
ATLANTA, Feb. 26, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today top-line safety and pharmacokinetic (PK) data from the Phase 1 multiple ascending dose...
Feb 16, 2016
ATLANTA, Feb. 16, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to its...
Feb 8, 2016
ATLANTA, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that the first patient has been dosed in a Phase 2 double-blind, randomized, placebo-c...
Feb 5, 2016
ATLANTA, Feb. 05, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced its financial results for the three month period ended December 31, 2015, which is the second quarter of the Company's 2016 fiscal year, and also provided an update on recent corporate developments. "I am very pleased today to report that sig...
Jan 29, 2016
ATLANTA, Jan. 29, 2016 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, February 5, 201...
Dec 18, 2015
ATLANTA, Dec. 18, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that it completed an initial Phase 1 single ascending dose (SAD) trial of BTA585, an o...
Dec 11, 2015
ATLANTA, Dec. 11, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's executive team will participate in the Guggenheim Securities 3rd Annual Bos...
Nov 11, 2015
ATLANTA, Nov. 11, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate ...
Nov 6, 2015
ATLANTA, Nov. 6, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced its financial results for the three month period ended September 30, 2015, which is the first...
Nov 2, 2015
ATLANTA, Nov. 2, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today the appointment of Mark P. Colonnese as Executive Vice President and Chief Financial Offi...
Oct 30, 2015
ATLANTA, Oct. 30, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, November 6, 2015 ...
Sep 22, 2015
ATLANTA, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate...
Sep 22, 2015
ATLANTA, Sept. 22, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced the appointments of Armando Anido and Michael Dunne, M.D. to its Board of D...
Sep 11, 2015
ATLANTA, Sept. 11, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals to treat infections that have limited therapeutic options, today announced its financial results for the fourth quarter and 2015 fiscal year ended Jun...
Sep 4, 2015
ATLANTA, Sept. 4, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that management will host a conference call on Friday, September 11, 201...
Sep 2, 2015
ATLANTA, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that Biota's CEO & President Joseph Patti, PhD will present a corporate ...
Aug 20, 2015
ATLANTA, Aug. 20, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) ("Biota" or the "Company"), a biopharmaceutical company focused on the discovery and development of direct-acting antivirals that address infections that have limited therapeutic options, announced today that it has commenced dosing in a 50-subject, randomized, pla...
Jun 3, 2015
ATLANTA, June 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) ("Biota" or the "Company") announced today that it has completed the acquisition of Anaconda Pharma, a privately-held biotechnology company based in Paris, France. The acquisition brings to Biota AP611074, a patented, direct-acting antiviral in clinical development for th...
May 7, 2015
ATLANTA, May 7, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, today announced its financial results for the three month period end...
Apr 30, 2015
ATLANTA, April 30, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that it will host a conference call on Thursday, May 7, 2015 at 9...
Mar 3, 2015
ATLANTA, March 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that Biota CEO & President Joseph Patti will prese...
Mar 3, 2015
ATLANTA, March 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) announced today that it has commenced dosing of patients in its Phase 2b SPIRITUS trial of vapendavir. The goal of the study is to enroll approximately 150 laboratory-confirmed human rhinovirus (HRV) infected patients with moderate-to-severe asthma from the United ...
Feb 26, 2015
Phase 2 Antiviral for the Treatment of Diseases Caused by Human Papillomavirus Strengthens Pipeline Conference Call Today at 9:00 A.M. EST ATLANTA, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals (Nasdaq:BOTA) (the "Company") announced today that it has entered into a definitive agreement to acquire Anaconda Pharma, a privat...
Feb 5, 2015
ATLANTA, Feb. 5, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended December 31, 2014, which is the second quarter of the Company's 2015 fiscal year, and also provided an update on recent corporate developments. "We are off to a great star...
Feb 3, 2015
ATLANTA, Feb. 3, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that Biota CEO & President Joseph Patti will presen...
Jan 29, 2015
ATLANTA, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company"), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that management will host a conference call on Thu...
Nov 7, 2014
ATLANTA, Nov. 7, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended September 30, 2014, which is the first quarter of the Company's 2015 fiscal year, and provided an update on recent corporate developments. "I believe 2015 is going to be a...
Oct 28, 2014
ATLANTA, Oct. 28, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Friday, November 7, 2014 at 9:00 a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will issu...
Sep 26, 2014
ATLANTA, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2014, and provided an update on a number of recent corporate developments. "As we continue to evaluate potential next steps for our laninamivir program,...
Sep 26, 2014
ATLANTA, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced a number of changes to management and its board of directors that will become effective October 1, 2014. The Board of Directors has appointed Dr. Joseph M. Patti as the Company's President and Chief Executive Officer and as ...
Sep 15, 2014
ATLANTA, Sept. 15, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that it will host a conference call on Friday, September 26, 2014 at 9:00 a.m. EDT to review the Company's fourth quarter and year-end 2014 financial results and provide an update on recent corporate developments. The Com...
Sep 4, 2014
ATLANTA, Sept. 4, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA), a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced today that it will present a poster describing preclinical data on BTA-C...
Aug 1, 2014
ATLANTA, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced top-line data from a randomized, double-blind, placebo-controlled, parallel-arm Phase 2 clinical trial comparing the safety and efficacy of a 40 mg and 80 mg dose of laninamivir octanoate ("LANI") to placebo. The trial, referred to as...
Jun 2, 2014
ATLANTA, June 2, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that following the completion of an operational review of the Company, its Board of Directors has adopted a plan to restructure the Company's operations. The adoption of the plan was the result of a recent decision by the Department o...
May 28, 2014
ATLANTA, May 28, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that its Executive Vice President, Dr. Joseph Patti, will present a corporate update at the Jefferies 2014 Global Healthcare Conference on Monday, June 2nd at 8:00 AM ET at The Grand Hyatt Hotel in New York City. The presentat...
May 8, 2014
ATLANTA, May 8, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that last night it received notice from the Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA), advising the Company...
May 6, 2014
ATLANTA, May 6, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month and nine month periods ended March 31, 2014, and provided an update on recent corporate developments. "We are pleased with the significant improvement in our operating results for the q...
Apr 30, 2014
ATLANTA, April 30, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that an interim update has been provided from the U.S. Department of Health and Human Services (HHS) and the Biomedical Advanced Research and Development Authority (BARDA) with respect to the Stop-Work Order the Company recently rec...
Apr 29, 2014
- Stop-Work Order Received Pending In Process Review Decision From BARDA - - Phase 2 IGLOO Top-Line Data Anticipated in Q3 2014 - ATLANTA, April 29, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ( the "Company") today announced that it has been notified by the U.S. Department of Health and Human Services (HHS) o...
Apr 29, 2014
Management to Host Conference Call to Review Q3 Financial Results Management to Present at Deutsche Bank 39th Annual Health Care Conference ATLANTA, April 29, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Tuesday, May 6, 2...
Feb 24, 2014
ATLANTA, Feb. 24, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 26th Annual ROTH Conference at 12:30 p.m. PDT, March 11, 2014, at The Ritz-Carlton, Dana Point in California. The presentation wil...
Feb 10, 2014
ATLANTA, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month and six month periods ended December 31, 2013, and provided an update on recent corporate developments. "Our financial results and lower overhead expenses for the quarter, notwithstan...
Feb 3, 2014
ATLANTA, Feb. 3, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Monday, February 10, 2014 at 9:00a.m EST to review the Company's second quarter financial results and provide an update on recent corporate developments. The Company will issue...
Jan 14, 2014
ATLANTA, Jan. 14, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") today announced that Guggenheim Securities, LLC has exercised its option to purchase an additional 872,085 common shares to cover over-allotments in connection with the Company's public offering of its common shares. The full exercise of ...
Jan 10, 2014
ATLANTA, Jan. 10, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") today announced that it has priced a public offering of 5,813,900 shares of its common stock at a purchase price of $4.30 per share for an aggregate offering amount of approximately $25 million. The net proceeds to Biota from the sale of ...
Jan 9, 2014
ATLANTA, Jan. 9, 2014 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") today announced its intention, subject to market and other conditions, to commence a public offering of its common stock. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes. ...
Dec 20, 2013
ATLANTA, Dec. 20, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") today reported that Daiichi Sankyo Company, Limited ("Daiichi Sankyo") has been granted regulatory approval in Japan to manufacture and market Inavir® Dry Powder Inhaler 20mg (generic name laninamivir octanoate) for the prevention of...
Dec 5, 2013
ATLANTA, Dec. 5, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that it has commenced dosing patients in the Northern Hemisphere portion of its ongoing Phase 2, randomized, double blind, placebo controlled, parallel arm clinical trial of laninamivir octanoate (LANI). The trial, referred to as "IGL...
Nov 19, 2013
ATLANTA, Nov. 19, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals Inc. ("Biota") (Nasdaq:BOTA) announced today that it has commenced dosing in two Phase 1 clinical trials of laninamivir octanoate ("LANI"), its long-acting neuraminidase inhibitor being developed for the treatment of influenza. One of the Phase 1 clinical trials is a single ce...
Nov 7, 2013
ATLANTA, Nov. 7, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") today announced its financial results for the three month period ended September 30, 2013. "As the flu season shifts from the southern to the northern hemisphere, we look forward to continuing enrollment in our Phase 2 IGLOO trial ...
Nov 3, 2013
Oct 28, 2013
ATLANTA, Oct. 28, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Thursday, November 7, 2013 at 9:00a.m. EST to review the Company's first quarter financial results and provide an update on recent corporate developments. The Company will iss...
Sep 18, 2013
ATLANTA, Sept. 18, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced financial results for its fourth quarter and fiscal year ended June 30, 2013, and provided an update on recent corporate developments and its financial guidance. "We are pleased with the transformation we have made since the...
Sep 11, 2013
ATLANTA, Sept. 11, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company") announced today that management will host a conference call on Wednesday, September 18, 2013 at 9:00a.m. EDT to review the Company's fourth quarter and fiscal year-end 2013 financial results and provide an update on recent corporate deve...
Aug 19, 2013
ATLANTA, Aug. 19, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) ("Biota" or the "Company"), a biopharmaceutical company focused on the discovery and development of anti-infective products to prevent and treat serious and potentially life-threatening infectious diseases, today announced changes to its Board of Directors, includi...
Jul 24, 2013
ATLANTA, July 24, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that Russell H. Plumb, its President and Chief Executive Officer, and other Company executives will present an update on the Company and its key programs for shareholders and other interested parties on the following dates: Tuesday, 30...
Jun 27, 2013
ATLANTA, June 27, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) today announced that its President and Chief Executive Officer, Russell H. Plumb, will present an update on the company at the 8th Annual JMP Securities Healthcare Conference at 2:30 p.m. EDT, July 10, 2013, at The St. Regis Hotel in New York City. The pres...
Jun 11, 2013
ATLANTA, June 11, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced that it has commenced dosing in a multi-national, randomized, double blind, placebo controlled, parallel arm Phase 2 clinical trial of laninamivir octanoate, a long-acting neuraminidase inhibitor. The trial, referred to as "IGLOO", w...
May 10, 2013
ATLANTA, May 10, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (Nasdaq:BOTA) (the "Company") today announced its financial results for the three month period ended March 31, 2013, and provided an update on recent corporate developments. In connection with announcing its financial results, the Company also announced that net sales of ...
May 6, 2013
ATLANTA, May 6, May 06, 2013 (GLOBE NEWSWIRE via COMTEX) -- Biota Pharmaceuticals, Inc. /quotes/...
Apr 15, 2013
ATLANTA, April 15, 2013 (GLOBE NEWSWIRE) -- Biota Pharmaceuticals, Inc. (BOTA) today announced that its Board of Directors has adopted a revised corporate strategy following the recent completion of management's strategic and operational review of the organization and its various development programs. The implementation of t...
Feb 12, 2013
ROCKVILLE, MD--(Marketwire - Feb 12, 2013) - Biota Pharmaceuticals, Inc. (NASDAQ: BOTA) LANI Influenza Program Advancing Toward Phase 2 Clinical Development Merge...
Nov 14, 2012
ROCKVILLE, MD -- (Marketwire) -- 11/14/12 -- Biota Pharmaceuticals, Inc. (NASDAQ:BOTA) today announced the appointment of Russell H. Plumb as its Chief Executive Officer and Joseph M. Patti, M.S.P.H., Ph.D. as Executive Vice President, Corporate Development...
Nov 9, 2012
ROCKVILLE, Md., Nov. 9, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today the effectiveness of its six-to-one reverse stock split (the "Reverse Stock Split") of Nabi common stock, which became effective as of 4:59 p.m., Eastern Standard Time, on November 8, 2012 (the "Effective Time"). Nabi also announced ...
Nov 9, 2012
Nov 9, 2012
The Scheme of Arrangement between Biota Holdings Limited (ASX:BTA; Biota) and the holders of its ordinary shares (Scheme) has been implemented today. Accordingly, all the ordinary shares in Biota have now been acquired by Nabi Biopharmaceuticals and which has changed its name to Biota Pharmaceuticals, Inc. (...
Nov 8, 2012
ROCKVILLE, Md., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its third quarter financial results for the three-month period ended September 30, 2012. The Company reported a net loss of $4.1 million, or $0.12 per share, compared to net income of $0.1 million, or zero per share, for the prior year period....
Nov 7, 2012
Nov 5, 2012
ROCKVILLE, Md., Nov. 5, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that Nabi's Board of Directors declared a special cash dividend in the aggregate of approximately $31.4 million, $1.108 per share of Nabi common stock. The special cash dividend is payable to stockholders of record on October 26, 2012 (which wa...
Nov 1, 2012
Oct 31, 2012
Oct 31, 2012
Oct 31, 2012
Oct 30, 2012
Oct 30, 2012
Oct 25, 2012
Z:M Navigator-October25, 2012-Deal snapshot: BIOTA, NABI SHAREHOLDERS BACK PLANNED MERGER ©2012 M2 COMMUNICATIONS http://www.m2.comAustralian influenza antivirals developer Biota Holdings Ltd (ASX:BTA) said that its planned tie-up with US vaccines maker Nabi Biopharmaceuticals (NASDAQ:NABI) had...
Oct 25, 2012
ROCKVILLE, Md., Oct. 25, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that its board of directors (the "Board") has established a ratio of one share-for-every six shares of the outstanding common stock for Nabi's proposed reverse stock split of all outstanding shares of common stock. Nabi anticipates that the re...
Oct 23, 2012
Z:M Navigator-October23, 2012-Biota, Nabi shareholders back planned merger ©2012 M2 COMMUNICATIONS http://www.m2.com23 October 2012 - Australian influenza antivirals developer Biota Holdings Ltd (ASX:BTA) said on Tuesday that its planned tie-up with US vaccines maker Nabi Biopharmaceuticals (NA...
Oct 23, 2012
Z:M Navigator-October23, 2012-M Navigator: Deal pipeline - 23 October ©2012 M2 COMMUNICATIONS http://www.m2.comThe following is a list of deals covered in detail by M Navigator this week:- TD BANK TO TAKE OVER TARGET'S US CREDIT CARD PORTFOLIOCanada's Toronto-Dominion Ba...
Oct 23, 2012
ROCKVILLE, Md., Oct. 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today the results of the reconvened special meeting of Nabi stockholders held on October 22, 2012 (the "Nabi Special Meeting"). Nabi also announced that the stockholders of Biota Holdings Limited (ASX:BTA.AX) approved the proposed business combinati...
Oct 19, 2012
ROCKVILLE, Md., Oct. 19, 2012 (GLOBE NEWSWIRE) -- Nabi today announced that, if the proposed business combination transaction between Nabi Biopharmaceuticals (Nasdaq:NABI) and Biota Holdings Limited (ASX:BTA.AX) is completed, each ordinary share of Biota capital stock will be transferred to Nabi in exchange for 0.749778075 of a share of Nabi com...
Oct 17, 2012
ROCKVILLE, Md., Oct. 17, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that the phase II study of NicVAX® (Nicotine Conjugate Immunotherapeutic) in combination with varenicline (Chantix or Champix) did not meet its primary endpoint.  A preliminary assessment of the trial data showed ...
Oct 16, 2012
ROCKVILLE, Md., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nadsaq:NABI) ("Nabi") today announced that the two major independent proxy advisory firms, Institutional Shareholder Services ("ISS") and Glass Lewis, have recommended that Nabi stockholders support the recently amended transaction agreement with Biota Holdings...
Oct 16, 2012
ROCKVILLE, Md., Oct. 16, 2012 (GLOBE NEWSWIRE) -- Nabi today announced that Nabi's Board of Directors has set October 26, 2012 as the record date with respect to the cash dividend to be paid in connection with the proposed business combination transaction of Nabi Biopharmaceuticals (Nadsaq:NABI) and Biota Holdings Limited (ASX:BTA.AX). As previo...
Sep 24, 2012
ROCKVILLE, Md., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that its Special Meeting of Stockholders scheduled for September 24, 2012 has been adjourned to provide additional time to solicit proxies to approve the proposals (the "Proposals") set forth in Nabi's definitive proxy materials dated August ...
Sep 19, 2012
NEW YORK, Sept. 19, 2012 /PRNewswire/ -- The Mangrove Partners Fund, L.P. ("Mangrove Partners"), one of the largest stockholders of Nabi Biopharmaceuticals (NasdaqGS: NABI), announced today that it is pleased that Nabi Biopharmaceuticals has responded to the concerns of its stockholders by amending the terms of the Transaction between Nabi Bio...
Sep 18, 2012
Z:M Navigator-September18, 2012-M Navigator: Deal pipeline - 18 September ©2012 M2 COMMUNICATIONS http://www.m2.comThe following is a list of deals covered in detail by M Navigator this week:- ELEMENT TRADING TECHNOLOGIES CLOSES REVERSE MERGER INTO UNITED TREATMENT CENTERS...
Sep 17, 2012
ROCKVILLE, Md., Sept. 17, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that it has agreed on revised terms with Biota Holdings Limited (ASX:BTA.AX) with respect to the proposed business combination transaction of the two companies. Nabi and Biota entered into an amendment deed to the merger implementation agreem...
Sep 12, 2012
NEW YORK, Sept. 12, 2012 /PRNewswire/ -- The Mangrove Partners Fund, L.P. ("Mangrove Partners"), one of the largest stockholders of Nabi Biopharmaceuticals (NasdaqGS: NABI), announced today that both Institutional Shareholder Services ("ISS") and Glass Lewis & Co. ("Glass Lewis") have recommended that stockholders support Mangrove Partn...
Sep 6, 2012
ROCKVILLE, Md. and MELBOURNE, Australia, Sept. 6, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nadsaq:NABI) today announced that Biota Holdings Limited (ASX:BTA.AX) has entered into advanced discussions with Russell H. Plumb, the former President and Chief Executive Officer of Inhibitex, Inc., with a view to agreeing on the terms and condit...
Aug 23, 2012
ROCKVILLE, Md., Aug. 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it is sending a letter to its stockholders, a copy of which is included below. The letter is in response to the statements made by Mangrove Partners Fund, L.P. and urges Nabi's stockholders to vote their WHITE proxy card accompanying Nabi...
Aug 23, 2012
ROCKVILLE, Md., Aug. 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that it is sending a letter to its stockholders, a copy of which is included below. The letter is in response to the statements made by Mangrove Partners Fund, L.P. and urges Nabi's stockholders to vote their WHITE proxy card accompanying Nabi...
Aug 23, 2012
Z:M Navigator-August23, 2012-M Navigator: Deal pipeline - 23 August ©2012 M2 COMMUNICATIONS http://www.m2.comThe following is a list of deals covered in detail by M Navigator this week:- MORGAN STANLEY INFRASTRUCTURE ARM TO BUY OUT SOUTHERN STARMorgan Stanley Infrastruct...
Aug 9, 2012
ROCKVILLE, Md., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its second quarter financial results for the three-month period ended June 30, 2012. The Company reported a net loss of $2.7 million, or $0.06 per share, compared to net loss of $4.6 million, or $0.11 per share, for the prior year period. ...
Aug 2, 2012
ROCKVILLE, Md., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that it will report its second quarter 2012 financial results on Thursday, August 9, after the market close. The company will host a live webcast and conference call at 4:30 p.m. EDT that day to discuss these results. The webcast ca...
Aug 2, 2012
ROCKVILLE, Md., Aug. 2, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) (the "Company") today announced the final results of its "modified Dutch auction" tender offer, which expired at 12:00 midnight, at the end of the day, New York City time, on Monday, July 30, 2012. In accordance with the terms and conditions of the tender ...
Jul 31, 2012
ROCKVILLE, Md., July 31, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) (the "Company") today announced the preliminary results of its "modified Dutch auction" tender offer, which expired at 12:00 midnight, at the end of the day, New York City time, on Monday, July 30, 2012. Based upon preliminary results, the Company expects...
Jul 19, 2012
ROCKVILLE, Md., July 19, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) (the "Company") announced today, in connection with its previously announced tender offer (for up to $23 million in value of its common stock at a price per share not less than $1.58 and not greater than $1.72), that it is waiving the following condition ...
Jul 2, 2012
ROCKVILLE, Md., July 2, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) (the "Company") today announced that it is commencing a "modified Dutch auction" tender offer for up to $23,000,000 of its common stock at a price per share not less than $1.58 and not greater than $1.72. The tender offer will expire at 12:00 midnight, at ...
May 10, 2012
ROCKVILLE, Md., May 10, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced its first quarter financial results for the three-month period ended March 31, 2011. The Company reported a net loss of $0.4 million, or $0.01 per share, compared to net income of $2.0 million, or $0.05 per share, for the prior year period....
May 3, 2012
ROCKVILLE, Md., May 3, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that it will report its first quarter 2012 financial results on Thursday, May 10, 2012, after the market close. The company will host a live webcast and conference call at 4:30 p.m. EDT that day to discuss these results. The webcast ...
Apr 24, 2012
Z:M Navigator-April24, 2012-Deal snapshot: AUSTRALIAN BIOTA TO MOVE TO US VIA COMBINATION WITH NABI ©2012 M2 COMMUNICATIONS http://www.m2.comAustralian influenza antivirals developer Biota Holdings Ltd (ASX:BTA) will take over US vaccines maker Nabi Biopharmaceuticals (NASDAQ:NABI) in a reverse...
Apr 23, 2012
http://media.marketwire.com/attachments/201010/653964_BIOTA_logo.jpg...
Apr 23, 2012
ROCKVILLE, Md., April 23, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced plans to merge with Biota Holdings Limited (ASX:BTA), a Melbourne, Australia company. The execution of the merger implementation agreement will form a combined company to be named Biota Pharmaceuticals, Inc. Biota Pharmaceuticals will be list...
Apr 23, 2012
Z:M Navigator-April23, 2012-M Navigator: Deal pipeline - 23 April ©2012 M2 COMMUNICATIONS http://www.m2.comThe following is a list of deals covered in detail by M Navigator this week:- SUFF SIGNS LOI FOR CONTROL OF MOBILE APPS DEVELOPERUS-based Suff Holdings (PINK:SUFF),...
Mar 14, 2012
ROCKVILLE, Md., March 14, 2012 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced fourth quarter and year-end financial results for the three and twelve month periods ended December 31, 2011. For the full year ended December 31, 2011, the Company's net loss was $4.5 million, or $0.11 per share, compared to a ne...
Page:
...
Next Last
 
= add release to Briefcase

Log In

Create an account